Science Daily: Pharmacology News

JULY 31, 2023

Chemists describe a powerful new way to create new-to-nature, 'unnatural' amino acids, which could find use in protein-based therapies and open up novel branches of organic chemistry.

Organic Chemistry 188

Organic Chemistry Therapies 188

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

New Drug Approvals

MARCH 26, 2025

Institute of Organic Chemistry and Biochemistry of the AS CR, v.v.i. Bavtavirine is part of highly active antitiretroviral therapy (HAART) treatment regimen. Benzonitrile, 4-[[4-amino-8-[4-[(1 E )-2-cyanoethenyl]-2,6-dimethylphenyl]-2-quinazolinyl]amino]- Gilead Sciences, Inc.;

Organic Chemistry 62

Organic Chemistry Science Therapies Treatment 62

Drug Target Review

SEPTEMBER 28, 2023

I started my journey in chemistry – first as an undergraduate and then in my PhD programme at the University of Houston, where I focused on organic chemistry and nucleic acids chemistry. Often, DNA technology is used in the development of new therapies.

DNA 116

DNA Organic Chemistry Science Virus 116

Drug Target Review

JUNE 8, 2023

Our vision was to give patients another option that would move away from chemotherapy-based treatments and closer to what we call a “targeted” therapy, meaning one with a more selective impact on the disease that spared normal cells as much as possible. in Organic Chemistry from the University of California, Berkeley.

Treatment 105

Treatment Organic Chemistry Research Disease 105

Drug Target Review

MAY 1, 2024

T-DM1, for example, is approved in patients with HER2-positive breast cancer and residual invasive cancer following neoadjuvant therapy. As we learn what therapies are more successful within specific patient populations, treatments can be tailored to increase the likelihood of being effective.

Drugs 69

Drugs FDA Approval Organic Chemistry Small Molecule 69

The Open Targets Blog

SEPTEMBER 21, 2023

After completing my PhD in organic chemistry at the University of Cambridge, I went to Canada as a Leverhulme Trust postdoctoral fellow. Photo credit: Jeff Dowling, EMBL-EBI What is your professional background? I’m a chemist by training. What are some of the challenges of your new role?

Organic Chemistry 82

Organic Chemistry Process Chemistry Small Molecule Science 82